OBJECTIVE: Selective laser amygdalohippocampotomy (SLAH) using magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is emerging as a treatment option for drug-resistant mesial temporal lobe epilepsy (MTLE). SLAH is less invasive than open resection, but there are limited series reporting its safety and efficacy, particularly in patients without clear evidence of mesial temporal sclerosis (MTS). METHODS: We report seizure outcomes and complications in our first 30 patients who underwent SLAH for drug-resistant MTLE between January 2013 and December 2016. We compare patients who required stereoelectroencephalography (SEEG) to confirm mesial temporal onset with those treated based on imaging evidence of MTS. RESULTS: Twelve patients with SEEG-confirmed, non-MTS MTLE and 18 patients with MRI-confirmed MTS underwent SLAH. MTS patients were older (median age 50 vs 30 years) and had longer standing epilepsy (median 40.5 vs 5.5 years) than non-MTS patients. Engel class I seizure freedom was achieved in 7 of 12 non-MTS patients (58%, 95% confidence interval [CI] 30%-86%) and 10 of 18 MTS patients (56%, 95% CI 33%-79%), with no significant difference between groups (odds ratio [OR] 1.12, 95% CI 0.26-4.91, P = .88). Length of stay was 1 day for most patients (range 0-3 days). Procedural complications were rare and without long-term sequelae. SIGNIFICANCE: We report similar rates of seizure freedom following SLAH in patients with MTS and SEEG-confirmed, non-MTS MTLE. Consistent with early literature, these rates are slightly lower than typically observed with surgical resection (60%-80%). However, SLAH is less invasive than open surgery, with shorter hospital stays and recovery, and severe procedural complications are rare. SLAH may be a reasonable first-line surgical option for patients with both MTS and SEEG confirmed, non-MTS MTLE. Wiley Periodicals, Inc.
OBJECTIVE: Selective laser amygdalohippocampotomy (SLAH) using magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is emerging as a treatment option for drug-resistant mesial temporal lobe epilepsy (MTLE). SLAH is less invasive than open resection, but there are limited series reporting its safety and efficacy, particularly in patients without clear evidence of mesial temporal sclerosis (MTS). METHODS: We report seizure outcomes and complications in our first 30 patients who underwent SLAH for drug-resistant MTLE between January 2013 and December 2016. We compare patients who required stereoelectroencephalography (SEEG) to confirm mesial temporal onset with those treated based on imaging evidence of MTS. RESULTS: Twelve patients with SEEG-confirmed, non-MTS MTLE and 18 patients with MRI-confirmed MTS underwent SLAH. MTS patients were older (median age 50 vs 30 years) and had longer standing epilepsy (median 40.5 vs 5.5 years) than non-MTS patients. Engel class I seizure freedom was achieved in 7 of 12 non-MTS patients (58%, 95% confidence interval [CI] 30%-86%) and 10 of 18 MTS patients (56%, 95% CI 33%-79%), with no significant difference between groups (odds ratio [OR] 1.12, 95% CI 0.26-4.91, P = .88). Length of stay was 1 day for most patients (range 0-3 days). Procedural complications were rare and without long-term sequelae. SIGNIFICANCE: We report similar rates of seizure freedom following SLAH in patients with MTS and SEEG-confirmed, non-MTS MTLE. Consistent with early literature, these rates are slightly lower than typically observed with surgical resection (60%-80%). However, SLAH is less invasive than open surgery, with shorter hospital stays and recovery, and severe procedural complications are rare. SLAH may be a reasonable first-line surgical option for patients with both MTS and SEEG confirmed, non-MTS MTLE. Wiley Periodicals, Inc.
Authors: Chengyuan Wu; Walter J Jermakowicz; Srijata Chakravorti; Iahn Cajigas; Ashwini D Sharan; Jonathan R Jagid; Caio M Matias; Michael R Sperling; Robert Buckley; Andrew Ko; Jeffrey G Ojemann; John W Miller; Brett Youngerman; Sameer A Sheth; Guy M McKhann; Adrian W Laxton; Daniel E Couture; Gautam S Popli; Alexander Smith; Ashesh D Mehta; Allen L Ho; Casey H Halpern; Dario J Englot; Joseph S Neimat; Peter E Konrad; Elliot Neal; Fernando L Vale; Kathryn L Holloway; Ellen L Air; Jason Schwalb; Benoit M Dawant; Pierre-Francois D'Haese Journal: Epilepsia Date: 2019-05-21 Impact factor: 5.864
Authors: Kim E Ono; Donald J Bearden; Elizabeth Adams; Jason Doescher; Sookyong Koh; Yaman Eksioglu; Robert E Gross; Daniel L Drane Journal: Epilepsy Behav Rep Date: 2020-06-02
Authors: Vejay N Vakharia; Rachel E Sparks; Kuo Li; Aidan G O'Keeffe; Fernando Pérez-García; Lucas G S França; Andrew L Ko; Chengyuan Wu; Joshua P Aronson; Brett E Youngerman; Ashwini Sharan; Guy McKhann; Sebastien Ourselin; John S Duncan Journal: Epilepsia Date: 2019-08-07 Impact factor: 5.864
Authors: Shasha Wu; Naoum P Issa; Maureen Lacy; David Satzer; Sandra L Rose; Carina W Yang; John M Collins; Xi Liu; Taixin Sun; Vernon L Towle; Douglas R Nordli; Peter C Warnke; James X Tao Journal: Front Neurol Date: 2021-05-17 Impact factor: 4.003
Authors: Kajol Marathe; Ali Alim-Marvasti; Karan Dahele; Fenglai Xiao; Sarah Buck; Aidan G O'Keeffe; John S Duncan; Vejay N Vakharia Journal: Front Neurol Date: 2021-12-09 Impact factor: 4.003